BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

607 related articles for article (PubMed ID: 15911236)

  • 21. Psychometric Testing of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy 20-Item Scale Using Pooled Chemotherapy-Induced Peripheral Neuropathy Outcome Measures Standardization and Alliance for Clinical Trials in Oncology A151408 Study Data.
    Smith EML; Banerjee T; Yang JJ; Bridges CM; Alberti P; Sloan JA; Loprinzi C
    Cancer Nurs; 2019; 42(3):179-189. PubMed ID: 29649081
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Updating your peripheral neuropathy "know-how".
    Marrs J; Newton S
    Clin J Oncol Nurs; 2003; 7(3):299-303. PubMed ID: 12793336
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Electronic versus paper-pencil methods for assessing chemotherapy-induced peripheral neuropathy.
    Knoerl R; Gray E; Stricker C; Mitchell SA; Kippe K; Smith G; Dudley WN; Lavoie Smith EM
    Support Care Cancer; 2017 Nov; 25(11):3437-3446. PubMed ID: 28577231
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patient-reported (EORTC QLQ-CIPN20) versus physician-reported (CTCAE) quantification of oxaliplatin- and paclitaxel/carboplatin-induced peripheral neuropathy in NCCTG/Alliance clinical trials.
    Le-Rademacher J; Kanwar R; Seisler D; Pachman DR; Qin R; Abyzov A; Ruddy KJ; Banck MS; Lavoie Smith EM; Dorsey SG; Aaronson NK; Sloan J; Loprinzi CL; Beutler AS
    Support Care Cancer; 2017 Nov; 25(11):3537-3544. PubMed ID: 28634656
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessing patient-reported peripheral neuropathy: the reliability and validity of the European Organization for Research and Treatment of Cancer QLQ-CIPN20 Questionnaire.
    Lavoie Smith EM; Barton DL; Qin R; Steen PD; Aaronson NK; Loprinzi CL
    Qual Life Res; 2013 Dec; 22(10):2787-99. PubMed ID: 23543373
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The relationship between observer-based toxicity scoring and patient assessed symptom severity after treatment for head and neck cancer. A correlative cross sectional study of the DAHANCA toxicity scoring system and the EORTC quality of life questionnaires.
    Jensen K; Bonde Jensen A; Grau C
    Radiother Oncol; 2006 Mar; 78(3):298-305. PubMed ID: 16524633
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical challenges: chemotherapy-induced peripheral neuropathy.
    Paice JA
    Semin Oncol Nurs; 2009 May; 25(2 Suppl 1):S8-19. PubMed ID: 19447319
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reliability and Validity of the EORTC QLQ-CIPN20 (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy 20-Item Scale) among Thai Women with Breast Cancer Undergoing Taxane-Based Chemotherapy.
    Rattanakrong N; Thipprasopchock S; Siriphorn A; Boonyong S
    Asian Pac J Cancer Prev; 2022 May; 23(5):1547-1553. PubMed ID: 35633537
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Putting evidence into practice: evidence-based interventions for chemotherapy-induced peripheral neuropathy.
    Visovsky C; Collins M; Abbott L; Aschenbrenner J; Hart C
    Clin J Oncol Nurs; 2007 Dec; 11(6):901-13. PubMed ID: 18063548
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of a European organization for research and treatment of cancer module to assess the quality of life of patients with proctitis after pelvic radiotherapy for malignancy.
    Spry N; Halkett G; Aoun S; Spry J; Yeoh E
    Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):522-8. PubMed ID: 18374505
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sweet bee venom pharmacopuncture for chemotherapy-induced peripheral neuropathy.
    Yoon J; Jeon JH; Lee YW; Cho CK; Kwon KR; Shin JE; Sagar S; Wong R; Yoo HS
    J Acupunct Meridian Stud; 2012 Aug; 5(4):156-65. PubMed ID: 22898064
    [TBL] [Abstract][Full Text] [Related]  

  • 32. EORTC QLQ-INFO26: a questionnaire to assess information given to cancer patients a preliminary analysis in eight countries.
    Arraras JI; Kuljanic-Vlasic K; Bjordal K; Yun YH; Efficace F; Holzner B; Mills J; Greimel E; Krauss O; Velikova G;
    Psychooncology; 2007 Mar; 16(3):249-54. PubMed ID: 16858744
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Chemotherapy-induced peripheral neuropathy].
    Noguchi E; Maeda Y
    Gan To Kagaku Ryoho; 2011 Nov; 38(11):1773-6. PubMed ID: 22083183
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy.
    Hausheer FH; Schilsky RL; Bain S; Berghorn EJ; Lieberman F
    Semin Oncol; 2006 Feb; 33(1):15-49. PubMed ID: 16473643
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Content Validity of a Chemotherapy-Induced Peripheral Neuropathy Patient-Reported Outcome Measure.
    Lavoie Smith EM; Haupt R; Kelly JP; Lee D; Kanzawa-Lee G; Knoerl R; Bridges C; Alberti P; Prasertsri N; Donohoe C
    Oncol Nurs Forum; 2017 Sep; 44(5):580-588. PubMed ID: 28820525
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Patient perceptions associated with chemotherapy-induced peripheral neuropathy.
    Tofthagen C
    Clin J Oncol Nurs; 2010 Jun; 14(3):E22-8. PubMed ID: 20529785
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The EORTC ophthalmic oncology quality of life questionnaire module (EORTC QLQ-OPT30). Development and pre-testing (Phase I-III).
    Brandberg Y; Damato B; Kivelä T; Kock E; Seregard S; ;
    Eye (Lond); 2004 Mar; 18(3):283-9. PubMed ID: 15004578
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The prevalence and pattern of chemotherapy-induced peripheral neuropathy among women with breast cancer receiving care in a large community oncology practice.
    Simon NB; Danso MA; Alberico TA; Basch E; Bennett AV
    Qual Life Res; 2017 Oct; 26(10):2763-2772. PubMed ID: 28664460
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Psychometric evaluation of the Arabic Version the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Chemotherapy-Induced Peripheral Neuropathy Questionnaire (EORTC QLQ-CIPN20).
    Abu Sharour L
    Appl Neuropsychol Adult; 2021; 28(5):614-618. PubMed ID: 31612735
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of the psychometric properties of the EORTC chemotherapy-induced peripheral neuropathy questionnaire (QLQ-CIPN20).
    Kieffer JM; Postma TJ; van de Poll-Franse L; Mols F; Heimans JJ; Cavaletti G; Aaronson NK;
    Qual Life Res; 2017 Nov; 26(11):2999-3010. PubMed ID: 28634676
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.